Gentium Reports Top Line Results From The Phase III Treatment Trial Of Defibrotide For Severe Veno-Occlusive Disease
Links shared publicly online about this topic.
- 1,807total visits
Gentium Reports Top Line Results From The Phase III Treatment Trial Of Defibrotide For Severe Veno-Occlusive Disease
Gentium s.p.a. (nasdaq: gent) announced top-line results from a historically controlled, multicenter, open label, phase iii trial designed to evaluate the safety and efficacy of 25 mg/kg/day of de
View full resource at medicalnewstoday.com
Tags: Disease and Condition
Most Recently Shared on August 21, 2009 at 10:44 am By:
Gentium Reports Top Line Results From The Phase III Treatment Trial Of Defibrotide For Severe Veno-Occlusive Dis.. http://bit.ly/LjmMT
Advertisement
